Clonidine Treatment of Alzheimer's Disease

Erich Mohr, Paul Fedio, Jerry Schlegel, Giovanni Fabbrini, Jill Williams, M. Maral Mouradian, Ulrike M. Mann, Jules J. Claus, Thomas N. Chase

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.

Original languageEnglish
Pages (from-to)376-378
Number of pages3
JournalArchives of Neurology
Volume46
Issue number4
DOIs
Publication statusPublished - 1989

Fingerprint

Clonidine
Alzheimer Disease
Cognition
Therapeutics
Placebos
Alzheimer's Disease
Replacement

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Mohr, E., Fedio, P., Schlegel, J., Fabbrini, G., Williams, J., Mouradian, M. M., ... Chase, T. N. (1989). Clonidine Treatment of Alzheimer's Disease. Archives of Neurology, 46(4), 376-378. https://doi.org/10.1001/archneur.1989.00520400030015

Clonidine Treatment of Alzheimer's Disease. / Mohr, Erich; Fedio, Paul; Schlegel, Jerry; Fabbrini, Giovanni; Williams, Jill; Mouradian, M. Maral; Mann, Ulrike M.; Claus, Jules J.; Chase, Thomas N.

In: Archives of Neurology, Vol. 46, No. 4, 1989, p. 376-378.

Research output: Contribution to journalArticle

Mohr, E, Fedio, P, Schlegel, J, Fabbrini, G, Williams, J, Mouradian, MM, Mann, UM, Claus, JJ & Chase, TN 1989, 'Clonidine Treatment of Alzheimer's Disease', Archives of Neurology, vol. 46, no. 4, pp. 376-378. https://doi.org/10.1001/archneur.1989.00520400030015
Mohr E, Fedio P, Schlegel J, Fabbrini G, Williams J, Mouradian MM et al. Clonidine Treatment of Alzheimer's Disease. Archives of Neurology. 1989;46(4):376-378. https://doi.org/10.1001/archneur.1989.00520400030015
Mohr, Erich ; Fedio, Paul ; Schlegel, Jerry ; Fabbrini, Giovanni ; Williams, Jill ; Mouradian, M. Maral ; Mann, Ulrike M. ; Claus, Jules J. ; Chase, Thomas N. / Clonidine Treatment of Alzheimer's Disease. In: Archives of Neurology. 1989 ; Vol. 46, No. 4. pp. 376-378.
@article{45a3ed03d083425fa23bdda2d2d62098,
title = "Clonidine Treatment of Alzheimer's Disease",
abstract = "A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.",
author = "Erich Mohr and Paul Fedio and Jerry Schlegel and Giovanni Fabbrini and Jill Williams and Mouradian, {M. Maral} and Mann, {Ulrike M.} and Claus, {Jules J.} and Chase, {Thomas N.}",
year = "1989",
doi = "10.1001/archneur.1989.00520400030015",
language = "English",
volume = "46",
pages = "376--378",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Clonidine Treatment of Alzheimer's Disease

AU - Mohr, Erich

AU - Fedio, Paul

AU - Schlegel, Jerry

AU - Fabbrini, Giovanni

AU - Williams, Jill

AU - Mouradian, M. Maral

AU - Mann, Ulrike M.

AU - Claus, Jules J.

AU - Chase, Thomas N.

PY - 1989

Y1 - 1989

N2 - A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.

AB - A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=0024515651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024515651&partnerID=8YFLogxK

U2 - 10.1001/archneur.1989.00520400030015

DO - 10.1001/archneur.1989.00520400030015

M3 - Article

C2 - 2650662

AN - SCOPUS:0024515651

VL - 46

SP - 376

EP - 378

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 4

ER -